Global Newsroom

• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate
• CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate
• A vaccine is anticipated to be available in 2021 if clinical trials are successful

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

Plasma-derived therapeutic with potential to treat serious complications of COVID-19.

CSL continues to provide medicines to patients around the world.

King of Prussia, Pa. and Sioux Falls, S.D.

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

CSL Limited's statement on Coronavirus

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.

Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.

Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.

CSL statement in response to media reports on case against Joseph Chiao

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination

Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long STEM literacy.

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, incorporating CSL’s Global Hub for Research and Translational Medicine.

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing